Anna Zisman
Internal Medicine · Chicago, ILNPI 1437317740
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,482 of the $39,942 with a category attached, or 78.8%. Novo Nordisk accounts for 63.2% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $25,286, 2.9 times the $8,597 reported in 2019. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $1174.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$25K
- Travere Therapeutics, Inc.$10K
- Idorsia Pharmaceuticals US Inc$5K
- Novo Nordisk Health Care AG$45
- AstraZeneca$35
What the payments were for
- Consulting fees$5,58614%
- Speaking & faculty fees$31,48279%
- Travel & lodging$2,0365%
- Food & beverage$8382%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $25,252 |
| Travere Therapeutics, Inc. | 15 | $9,747 |
| Idorsia Pharmaceuticals US Inc | 1 | $4,865 |
| Novo Nordisk Health Care AG | 1 | $45 |
| AstraZeneca | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rivfloza$17,566
- (815) Thiola$8,662
- Tryvio$4,865
How this compares
$39,942 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Thiola EcTiopronin | 12 | $141,724 |
| Potassium Citrate ErPotassium Citrate | 43 | $6,249 |
| Potassium Chloride | 53 | $1,240 |
| Amiloride Hcl | 35 | $839 |
| Indapamide | 48 | $798 |
| Chlorthalidone | 52 | $746 |
| Torsemide | 27 | $552 |
| Losartan Potassium | 36 | $292 |
| Amlodipine Besylate | 53 | $215 |
| Lisinopril | 14 | $194 |
| Prednisone | 13 | $109 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $72 |
| Allopurinol | 14 | $54 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Chicago
- Merle DiamondChicago$1.1M
- Robert KushnerChicago$516K
- Romeo UrsuaChicago$420K
- Peter O DonnellChicago$318K
- George UrbanChicago$258K
- Kristen PallokChicago$256K
- George NissanChicago$252K
- Luke LaffinChicago$162K
- Daniel CatenacciChicago$161K
- Hiren ShahChicago$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.